Efficacy of Eculizumab in the Treatment of Recurrent Atypical Hemolytic-Uremic Syndrome After Renal Transplantation
- 15 April 2010
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (7), 903-904
- https://doi.org/10.1097/tp.0b013e3181ccd80d
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Thrombomodulin Mutations in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2009
- Eculizumab for Congenital Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2009
- Eculizumab for Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2009
- Advances in understanding of pathogenesis of aHUS and HELLPBritish Journal of Haematology, 2008
- Hemolytic uremic syndrome recurrence after renal transplantationPediatric Transplantation, 2008
- Pathogenesis and prognosis of thrombotic microangiopathyClinical and Experimental Nephrology, 2007
- Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for ApheresisTransfusion, 2003